(Q33237559)

24 July 2017

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers (English)

1 reference

single-nucleotide polymorphism

24 July 2017

1 reference

1 reference

Jeremy P Blaydes

3

0 references

Peter Johnson

object named as

Peter W Johnson

5

0 references

Diana Eccles

object named as

Diana M Eccles

6

0 references

author name string

Ellen R Copson

1

1 reference

24 July 2017

Helen E White

2

1 reference

24 July 2017

David O Robinson

4

1 reference

24 July 2017

language of work or name

English

0 references

publication date

24 March 2006

1 reference

24 July 2017

1 reference

24 July 2017

6

1 reference

24 July 2017

1

1 reference

29 June 2019

page(s)

80

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-6-80

24 July 2017

0 references

cites work

The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Collaboration of Brca1 and Chk2 in tumorigenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Insights into the functions of BRCA1 and BRCA2.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

BRCA1 physically associates with p53 and stimulates its transcriptional activity.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

BRCA1 is a component of the RNA polymerase II holoenzyme

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Amplification of a gene encoding a p53-associated protein in human sarcomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-80

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-80

Brca1 required for T cell lineage development but not TCR loci rearrangement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-80

Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-80

No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1483833

Abnormal expression of MDM-2 in breast carcinomas

31 October 2018

1 reference

12 December 2020

p53 mutations in BRCA1-associated familial breast cancer

1 reference

12 December 2020

Mammary tumor formation in p53- and BRCA1-deficient mice

1 reference

12 December 2020

Increased frequency ofTP53 mutations inBRCA1 andBRCA2 ovarian tumours

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-6-80

1 reference

Dimensions Publication ID

24 July 2017

0 references

1 reference

24 July 2017

1 reference